Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Microcap Kitchen Canadian Stocks -- Ignore unavailable to you. Want to Upgrade?

To: purse who wrote (48923)	4/5/2019 1:41:44 PM
From: Claude Cormier	Read Replies (1) \| Respond to of 49402

And you never know when they will announce a deal with Walmart!

To: purse who wrote (48923)	4/8/2019 12:06:46 PM
From: kidl	1 Recommendation Recommended By Claude Cormier Read Replies (1) \| Respond to of 49402

ENW ... Further to the issue of manufacturing capacity / system lead-in times ... On July 18 of last year ENW signed a 6 months collaboration / licence option agreement with GEA (see NR below). I was able to confirm that this “deal” is not dead and an update should be issued “soon”. If they come to an agreement, GEA’s manufacturing capacity could go a long way towards speeding up the process. EnWave inks collaboration, licence option deal with GEA 2018-07-18 10:11 ET - News Release Dr. Tim Durance reports ENWAVE SIGNS COLLABORATION AND LICENCE OPTION AGREEMENT WITH GEA, AN INDUSTRY LEADING PHARMACEUTICAL EQUIPMENT MANUFACTURER EnWave Corp. has signed a collaboration and licence option agreement with GEA Lyophil GmbH, a liquid dosage organization of the business application pharma of the GEA Group. GEA is a major global supplier of GMP lyophilization, and loading and unloading systems for the pharmaceutical sector, and one of the largest suppliers of process technology for the global food processing industry and a wide range of other industries. During the six-month term of the collaboration, the company and GEA will jointly evaluate a potential partnership to facilitate the manufacture and deployment of continuous cGMP REV lyophilization equipment into the global pharmaceutical sector. During the term of the agreement, GEA will work with EnWave's experienced engineering and biomaterials team to conduct tests using REV pharmaceutical lyophilization equipment at the company's facility in Delta, B.C., Canada. GEA will evaluate the commercial viability of a partnership and the potential integration of EnWave's technology into processing solutions for pharmaceutical applications. The agreement further grants GEA an exclusive option during the term to negotiate an agreement to manufacture and sell equipment for production of pharmaceutical and biotechnology products using EnWave's patented dehydration technology. If the collaboration is successful, a potential partnership between GEA and EnWave could accelerate the commercialization of EnWave's REV technology for rapid dehydration of pharmaceutical products, by pairing EnWave's patented technology with GEA's industry-leading manufacturing practices and market reach. All other terms of the agreement are confidential.